Efficacy and applicability of topical cannabidiol-based treatment in psoriasis patient, randomized, placebo, controlled trial

Phase 4

• Conditions: plaque type psoriasis patients with mild severity; Psoriasis, cannabis, cannabinoid, cannabidiol, marijuana

• Registration Number: TCTR20210529001
• Lead Sponsor: Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-05-29
• Study Completion: 2021-09-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

1. male/female 18-70 years 2. plaque type psoriasis, mild severity 3.able to comply with study protocol 4. willingly inform consent

Exclusion Criteria

1. unable to stop previous treatment (washout period; systemic treatment 4 weeks, topical treatment 2 weeks). 2. abnormal liver or renal function 3. psychological disorder 4. Pregnant or lactating women 5. allergic to study product.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
PASI (baseline, week 2, 4, 8, 12) PASI

Secondary Outcome Measures

Name	Time	Method
Side effects week 2, 4, 8, 12 Side effects